Identification and validation of a plasma metabolomics-based model for risk stratification of intrahepatic cholangiocarcinoma
- 12 July 2023
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (13) , 12365-12377
Abstract
Background Liver resection is the mainstay of curative treatment for intrahepatic cholangiocarcinoma (ICC) while the postoperative prognosis varies greatly, with no recognized biomarker. We aimed to identify the plasma metabolomic biomarkers that could be used for preoperative risk stratification of ICC patients. Methods 108 eligible ICC patients who underwent radical surgical resection between August 2012 and October 2020 were enrolled. Patients were randomly divided into a discovery cohort (n = 76) and a validation cohort (n = 32) by 7:3. Metabolomics profiling of preoperative plasma was performed and clinical data were collected. The least absolute shrinkage and selection operator (LASSO) regression, Cox regression, and receiver operating characteristic (ROC) analyses were used to screen and validate the survival-related metabolic biomarker panel and construct a LASSO-Cox prediction model. Results 10 survival-related metabolic biomarkers were used for construction of a LASSO-Cox prediction model. In the discovery and validation cohorts, the LASSO-Cox prediction model achieved an AUC of 0.876 (95%CI: 0.777–0.974) and 0.860 (95%CI: 0.711–1.000) in evaluating 1-year OS of ICC patients, respectively. The OS of ICC patients in the high-risk group was significantly worse than that in the low-risk group (discovery cohort, p < 0.0001; validation cohort: p = 0.041). Also, the LASSO-Cox risk score (HR 2.43, 95%CI: 1.81–3.26, p < 0.0001) was a significant independent risk factor associated with OS. Conclusions The LASSO-Cox prediction model has potential as an important tool in evaluating the OS of ICC patients after surgical resection and can be used as prediction tools to implement the best treatment options that could result in better outcomes.Keywords
Funding Information
- National Natural Science Foundation of China (82202949, 81771958)
- China Postdoctoral Science Foundation (2022M723627)
- National Science Fund for Distinguished Young Scholars (81825013)
- Basic and Applied Basic Research Foundation of Guangdong Province (2019A1515111168)
This publication has 43 references indexed in Scilit:
- Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysisJournal of Surgical Oncology, 2016
- Feeding the TCA cycle in vivoNature Reviews Cancer, 2016
- Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics studyBMC Medicine, 2016
- Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic CholangiocarcinomaAnnals of Surgical Oncology, 2014
- Guidelines for the diagnosis and management of intrahepatic cholangiocarcinomaJournal of Hepatology, 2014
- Inositol Phosphate Recycling Regulates Glycolytic and Lipid Metabolism That Drives Cancer AggressivenessACS Chemical Biology, 2014
- Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial HepatectomyJournal of Clinical Oncology, 2013
- Quercetin in Cancer Prevention and TherapyIntegrative Cancer Therapies, 2012
- Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node AssessmentJournal of Clinical Oncology, 2011
- Prognostic versus predictive value of biomarkers in oncologyEuropean Journal of Cancer, 2008